Purple Biotech (PPBT) Competitors $2.47 -0.15 (-5.73%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends PPBT vs. AIM, NLSP, SNSE, WENA, SLGL, TLPH, AWH, IPA, NKGN, and INDPShould you be buying Purple Biotech stock or one of its competitors? The main competitors of Purple Biotech include AIM ImmunoTech (AIM), NLS Pharmaceutics (NLSP), Sensei Biotherapeutics (SNSE), ANEW Medical (WENA), Sol-Gel Technologies (SLGL), Talphera (TLPH), Aspira Women's Health (AWH), ImmunoPrecise Antibodies (IPA), NKGen Biotech (NKGN), and Indaptus Therapeutics (INDP). These companies are all part of the "pharmaceutical products" industry. Purple Biotech vs. AIM ImmunoTech NLS Pharmaceutics Sensei Biotherapeutics ANEW Medical Sol-Gel Technologies Talphera Aspira Women's Health ImmunoPrecise Antibodies NKGen Biotech Indaptus Therapeutics AIM ImmunoTech (NYSE:AIM) and Purple Biotech (NASDAQ:PPBT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends, risk and profitability. Is AIM or PPBT more profitable? Purple Biotech has a net margin of 0.00% compared to AIM ImmunoTech's net margin of -12,594.21%. Purple Biotech's return on equity of -54.92% beat AIM ImmunoTech's return on equity.Company Net Margins Return on Equity Return on Assets AIM ImmunoTech-12,594.21% -421.73% -147.54% Purple Biotech N/A -54.92%-43.29% Do institutionals & insiders hold more shares of AIM or PPBT? 12.0% of AIM ImmunoTech shares are held by institutional investors. Comparatively, 9.6% of Purple Biotech shares are held by institutional investors. 0.0% of AIM ImmunoTech shares are held by company insiders. Comparatively, 3.0% of Purple Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation and earnings, AIM or PPBT? Purple Biotech has lower revenue, but higher earnings than AIM ImmunoTech. AIM ImmunoTech is trading at a lower price-to-earnings ratio than Purple Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAIM ImmunoTech$200K63.33-$28.96M-$0.47-0.42Purple BiotechN/AN/A-$19.88M-$8.79-0.28 Does the media prefer AIM or PPBT? In the previous week, AIM ImmunoTech had 6 more articles in the media than Purple Biotech. MarketBeat recorded 13 mentions for AIM ImmunoTech and 7 mentions for Purple Biotech. AIM ImmunoTech's average media sentiment score of 0.33 beat Purple Biotech's score of -0.03 indicating that AIM ImmunoTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment AIM ImmunoTech 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Purple Biotech 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Does the MarketBeat Community favor AIM or PPBT? AIM ImmunoTech received 41 more outperform votes than Purple Biotech when rated by MarketBeat users. However, 94.44% of users gave Purple Biotech an outperform vote while only 82.86% of users gave AIM ImmunoTech an outperform vote. CompanyUnderperformOutperformAIM ImmunoTechOutperform Votes5882.86% Underperform Votes1217.14%Purple BiotechOutperform Votes1794.44% Underperform Votes15.56% Do analysts prefer AIM or PPBT? AIM ImmunoTech presently has a consensus target price of $3.00, indicating a potential upside of 1,409.05%. Purple Biotech has a consensus target price of $33.00, indicating a potential upside of 1,236.03%. Given AIM ImmunoTech's higher probable upside, equities research analysts plainly believe AIM ImmunoTech is more favorable than Purple Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score AIM ImmunoTech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Purple Biotech 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more risk and volatility, AIM or PPBT? AIM ImmunoTech has a beta of -0.36, meaning that its share price is 136% less volatile than the S&P 500. Comparatively, Purple Biotech has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500. SummaryAIM ImmunoTech and Purple Biotech tied by winning 8 of the 16 factors compared between the two stocks. Ad Crypto 101 Media“Sleeping Giant” Crypto Set to Explode…What if I told you there's a crypto that could make Bitcoin look like small change? We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Get Purple Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PPBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PPBT vs. The Competition Export to ExcelMetricPurple BiotechPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.66M$6.39B$4.99B$8.73BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-0.319.86131.1817.48Price / SalesN/A323.271,217.1989.76Price / CashN/A22.1633.2632.46Price / Book0.105.524.684.67Net Income-$19.88M$152.72M$117.89M$225.02M7 Day Performance0.73%-3.74%-2.26%-2.11%1 Month Performance-37.07%-8.10%-3.84%-0.04%1 Year PerformanceN/A29.64%30.03%24.52% Purple Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PPBTPurple Biotech2.2367 of 5 stars$2.47-5.7%$33.00+1,236.0%N/A$3.29MN/A-0.2820High Trading VolumeAIMAIM ImmunoTech2.177 of 5 stars$0.20+11.2%$3.00+1,409.1%-58.4%$12.67M$200,000.00-0.4020News CoverageHigh Trading VolumeNLSPNLS Pharmaceutics1.2519 of 5 stars$3.29+3.5%N/A+808.6%$12.55MN/A0.006Gap DownSNSESensei Biotherapeutics4.6938 of 5 stars$0.50+4.2%$4.33+770.1%-17.5%$12.53MN/A-0.4040News CoverageHigh Trading VolumeWENAANEW MedicalN/A$0.73-0.5%N/AN/A$12.51MN/A0.00N/AGap UpSLGLSol-Gel Technologies3.6264 of 5 stars$0.44+2.3%$5.00+1,033.8%-69.4%$12.29M$1.55M-1.2750News CoverageTLPHTalphera2.7155 of 5 stars$0.71+6.0%$4.50+537.0%N/A$12.03M$650,000.00-0.9719Gap UpAWHAspira Women's Health1.5871 of 5 stars$0.73+2.8%$4.40+502.7%-78.1%$11.72M$9.15M0.00110Analyst ForecastGap UpIPAImmunoPrecise Antibodies2.0702 of 5 stars$0.39-4.9%$6.00+1,454.8%-69.8%$11.13M$24.09M-0.5280NKGNNKGen BiotechN/A$0.31+6.8%N/A-89.6%$11.07M$80,000.00-0.06N/AINDPIndaptus Therapeutics3.0721 of 5 stars$1.07+3.9%$8.50+694.4%-50.0%$10.91MN/A-0.606 Related Companies and Tools Related Companies AIM ImmunoTech Competitors NLS Pharmaceutics Competitors Sensei Biotherapeutics Competitors ANEW Medical Competitors Sol-Gel Technologies Competitors Talphera Competitors Aspira Women's Health Competitors ImmunoPrecise Antibodies Competitors NKGen Biotech Competitors Indaptus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:PPBT) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | Sponsored31 Billionaires Are Loading Up on This SectorWhy are 31 of the world's richest billionaires, like Warren Buffett, Jeff Bezos, the Walton family, and Bill G...InvestorPlace | SponsoredFormer Trump advisor releases terrifying warningGoldman Sachs: 300 Million People Are At Risk The mainstream media are practically ignoring the most import...Wide Moat Research | SponsoredMy favorite credit card just increased its sign-up bonusTired of getting average credit card rewards? This credit card just increased its sign-up bonus to 75,000 bonu...Card Ratings | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
